ONE ACTIVE MOLECULE†
VYZULTA® is thought to lower intraocular pressure by increasing outflow of
aqueous humor through both uveoscleral and trabecular meshwork routes.†
PrVYZULTA® (latanoprostene bunod ophthalmic solution, 0.024% w/v)
is indicated for the reduction of intraocular pressure in patients
with open-angle glaucoma or ocular hypertension.
† Clinical significance unknown.